Past literature recommends varied combinations of 2 or more anti-hypertensive drugs as polypill therapy for Myocardial Infarction (MI). OBJECTIVES: This study examined the utilization pattern and predictors of  the most combinations  for MI patients. METHODS: Data from 2009 Medical Expenditure Panel Survey (MEPS) was employed to examine the use of anti-hypertensive drug combinations among MI patients, defined by ICD-9-CM code ‘410’. Using MEPS sampling weights, descriptive analysis and survey logistic were  used to evaluate prevalence and predictors of utilizing 2 or more anti-hypertensive drug combinations among MI patients.  RESULTS: An estimated 5.91million patients (1.93%, 95%CI: 1.70%-2.15%) were diagnosed with MI in 2009. Of these, 5.03 million patients (85.92%, 95%CI: 82.62%-89.22%) were using at least one anti-hypertensive and 3.60million patients (60.87%, 95%CI: 56.19%-65.55%) were using a combination of ≥2 anti-hypertensives. Most frequently utilized combination of ≥2 anti-hypertensives was of Angiotensin inhibitors or Angiotensin receptor blockers (ACEARB) and Beta-blockers (BBS) with a prevalence of 2.41million patients (40.86%, 95%CI: 36.35%-45.36%). Multivariate analysis revealed Hypertension (OR 2.43: 1.49 – 3.96), Congestive Heart Failure or CHF (OR 3.05: 1.33 – 7.00), and Chronic Atherosclerosis (OR 2.08: 1.32 – 3.29) as its statistically significant predictors of two or more hypertensive combinations. The most prevalent combination of ≥3 anti-hypertensives was for a combination of ACEARB, BBs and Diuretics  with a prevalence of 1.19 million (20.11%, 95%CI: 16.52%-23.70%). The significant predictors of utilizing this combination were Presence of any limitation (OR 3.47: 1.69 – 7.13), Hypertension (OR 2.22: 1.08 – 4.58), CHF (OR 6.10: 2.92 – 12.73), and Chronic Atherosclerosis (OR 2.03: 1.12 – 3.70). CONCLUSIONS: Combinations of ACEARB and BBs with or without Diuretics were the most commonly used combinations in patients with MI. Comorbid hypertension, CHF and Chronic atherosclerosis were the primary disease-based  predictors of these combinations.